Daewoong Pharmaceutical Launches New GERD Drug 'Pexuclu' in the Philippines

Daewoong Pharmaceutical is introducing its new drug for gastroesophageal reflux disease (GERD), 'Pexuclu' (active ingredient: Pexuprazan Hydrochloride), to overseas markets.

On the 27th of last month, Daewoong Pharmaceutical held a launch event for Pexuclu at the Shangri-La Hotel in Manila, Philippines, where it presented the current status of GERD treatment, the advantages of Pexuclu, and clinical results to over 350 local medical professionals, the company announced on the 1st.

This marks Daewoong Pharmaceutical's launch of Pexuclu in the Philippines just one year after it was approved as Korea's 34th domestic new drug last year. It is also the first overseas expansion case for Pexuclu.

At the local event, Professor Lee Guk-rae of the Department of Gastroenterology at Seoul Boramae Hospital, who co-chaired the session, said, "Compared to existing proton pump inhibitors (PPIs), Pexuclu, a drug from a completely different class, is expected to become a treatment option for GERD among doctors and patients in the Philippines." Professor Kim Ji-won of the same department presented the advantages and effects of Pexuclu and added, "We hope that the domestically developed new drug Pexuclu will expand into more countries in the future."

The local distribution, sales, and marketing of Pexuclu will be handled by PNSV Asia, a group company of 'SV More,' Daewoong Pharmaceutical's partner for over 10 years. The SV More group has been responsible for the sales and marketing of Daewoong Pharmaceutical's gastrointestinal products such as the liver function enhancer 'Urusa' and the digestive aid 'Beaje.'

Developed by Daewoong Pharmaceutical since 2008, Pexuclu belongs to the potassium-competitive acid blocker (P-CAB) class of drugs, distinguishing it from existing PPI-based GERD treatments. It features improvements over PPIs, such as faster onset of action, reduced dietary influence, and fewer drug interactions. Among GERD treatments, Pexuclu has the longest half-life of 9 hours. A single dose provides prolonged efficacy, significantly reducing nighttime heartburn symptoms.

Jeon Seung-ho, CEO of Daewoong Pharmaceutical, stated, "Starting with the launch in the Philippines, we will actively expand our presence in the global GERD market and accelerate efforts to achieve 1 trillion KRW in global sales by 2030. Furthermore, beyond the currently secured indications for erosive GERD treatment and improvement of acute and chronic gastritis mucosal lesions, we will pursue additional indications and expand formulations to enhance dosing convenience and competitiveness."

This content was produced with the assistance of AI translation services.